BiomEdit
German Plata has an extensive work experience in scientific research. They started their career as a Research Assistant at CIAT from April 2006 to August 2008. They then worked as a Graduate Research Assistant at Columbia University from September 2008 to September 2013. After that, German joined Columbia University in the City of New York as a Postdoctoral Researcher from November 2013 to October 2016. They continued at the same institution as an Associate Research Scientist from October 2016 to July 2019, focusing on microbial eco-evolutionary dynamics and molecular evolution across various species.
In 2019, German Plata joined Elanco as a Research Scientist in Systems Biology. They held this role from July 2019 to October 2021, during which they also served as a Senior Research Scientist from October 2021 to December 2021. Subsequently, German worked as a Senior Research Scientist at MBRD Service Company, LLC from January 2022 to April 2022, and currently holds the position of Senior Research Scientist at BiomEdit starting from April 2022.
German Plata obtained a Bachelor of Science degree in Biology from Universidad Nacional de Colombia, which they attended from 2001 to 2005. Following this, they pursued a Doctor of Philosophy (PhD) degree in Biomathematics, Bioinformatics, and Computational Biology at Columbia University from 2008 to 2013.
This person is not in any offices
BiomEdit
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of themicrobiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics.